Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein | R&D Systems 443-KD-050 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

R&D Systems

product type :

protein

product name :

Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein

catalog :

443-KD-050

quantity :

50 ug

price :

456 USD

citations: 10

Reference
Mashayekhi V, Xenaki K, van Bergen en Henegouwen P, Oliveira S. Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy. Cancers (Basel). 2020;12: pubmed publisher
Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells. 2020;9: pubmed publisher
Ikeuchi T, de Vega S, Forcinito P, Doyle A, Amaral J, Rodriguez I, et al. Extracellular Protein Fibulin-7 and Its C-Terminal Fragment Have In Vivo Antiangiogenic Activity. Sci Rep. 2018;8:17654 pubmed publisher
Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, et al. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Mol Ther Oncolytics. 2016;3:16024 pubmed
Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd F, StÃ¥hl S, et al. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep. 2014;4:7518 pubmed publisher
Wuest T, Carr D. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J Exp Med. 2010;207:101-15 pubmed publisher
Ponticelli S, Marasco D, Tarallo V, Albuquerque R, Mitola S, Takeda A, et al. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem. 2008;283:34250-9 pubmed publisher
Getmanova E, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol. 2006;13:549-56 pubmed
Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, et al. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Ther. 2006;13:1198-205 pubmed
Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, et al. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology. 2005;41:1233-40 pubmed

product information

master code :

443-KD

SKU :

443-KD-050

product name :

Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein

unit size :

50 ug

description :

The Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein from R&D Systems is derived from NS0. The Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein has been validated for the following applications: Bioactivity.

target :

VEGFR2/KDR/Flk-1

category :

Proteins and Enzymes

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with BSA as a carrier protein.

conjugate :

Unconjugated

purity :

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

species :

Mouse

observed molecular weight :

166-191 kDa, reducing conditions

theoretical molecular weight :

110 kDa (monomer)

gene symbol :

Kdr

details of functionality :

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 10-30 ng/mL in the presence of 5 ng/mL recombinant mouse VEGF.

endotoxin note :

<0.10 EU per 1 ╡g of the protein by the LAL method.

accessionNumbers :

P35918

applications :

Bioactivity

source long :

Mouse myeloma cell line, NS0-derived mouse VEGFR2/KDR/Flk-1 protein Mouse VEGFR2 (Ala20-Glu762) Accession # P35918 IEGRMD Human IgG1 (Pro100-Lys330) 6-His tag N-terminus C-terminus

source short :

NS0

USD :

456 USD

alt names :

CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.